healio.com

7 articles in the TruthFoundry index. Each links out to the original.

• Three Generations of Rheumatologists Assess Evolution of Treatments and AI · Rheumatologists from three generations discuss the evolution of therapeutic options and the emergence of AI in the field.
• Deucravacitinib Shows Superior Efficacy in Psoriatic Arthritis at 52 Weeks · Deucravacitinib demonstrated sustained superior efficacy and tolerability versus placebo in adults with active psoriatic arthritis through 52 weeks.
• FDA Approves Lisraya as First Oral Drug for Dermatomyositis · The FDA approved Lisraya (brepocitinib) as the first oral treatment for adult dermatomyositis based on phase 3 trial data.
• ACR warns CMS Medicare drug negotiation rule may restrict access · The American College of Rheumatology warns a new CMS rule could create reimbursement gaps and limit access to biologic drugs.
• Brepocitinib Shows Rapid, Durable Efficacy in Cutaneous Dermatomyositis · Analysis of the phase 3 VALOR trial shows brepocitinib rapidly improves skin symptoms in cutaneous dermatomyositis.
• Women Rheumatologists Face Glass Cliff and Likability Penalty · Sheetal Desai, MD, reports women rheumatologists earn less and face systemic bias in leadership.
• Healio Editor Discusses US Probe of Pharma Companies in China and Compounded Drug Risks · Healio's Leonard Calabrese discusses US congressional investigations into pharma companies in China and the risks of compounded medications.